Analysts Issue Forecasts for MRK FY2029 Earnings
Analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Merck & Co., Inc. in a research report issued to clients and investors on Friday, January 24th. Leerink Partnrs analyst D.
Optimistic Buy Rating for Merck & Co. Driven by Winrevair Projections and Financial Strength
In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...
China investigates generic drugs over safety concerns
Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but ...
I came home to find my husband wearing a DRESS with a padded bra, thick make-up, red nail polish and heels. It turned out he'd had a cross-dressing fetish for years an…
The house was quiet when I let myself in. I walked into the living room, expecting to find my husband, instead, there was a ...
President Trump’s First Week Hammered Public Health
The first week of President Donald Trump’s second term included several executive orders and actions that will be detrimental ...
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...